We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

1 hedge funds and large institutions have $30 invested in Statera Biopharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 4 → 1 (-3)

99% less capital invested

Capital invested by funds: $3.29K → $30 (-$3.26K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3K
2
IA
IFP Advisors
Florida
-$271
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
1
Tucker Asset Management
Colorado
$30 – – –
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
– -$3K -211,836 Closed
IA
3
IFP Advisors
Florida
– -$271 -87 Closed

STAB Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2023, worth a combined $30 — down 99% from $3.29K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of STAB and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Acadian Asset Management, exiting entirely with an estimated $3K sold.

  • 1 institutional investor held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2023, down from 4 in Q1 2023.
  • Funds reported $30 of Statera Biopharma, Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -3 holders.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q2 2023 was Acadian Asset Management, an estimated $3K sold.

Based on aggregated 13F filings for Q2 2023.